This phase III trial is evaluating the effectiveness and safety of chemotherapy (carboplatin and paclitaxel) in combination with two targeted therapies (Pembrolizumab and Olaparib) to treat women with epithelial ovarian, fallopian tube or primary peritoneal cancer..
This trial is treating patients with ovarian, fallopian tube and primary peritoneal cancers.
This is a systemic treatment.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
- ENGOT-OV43, MK-7339-001, 2018-001973-25, 194619, ENGOT 001, CTA ID:CT1145
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Patients eligible to participate in this trial will receive an initial 3-week cycle of carboplatin and paclitaxel administered intravenously. After the initial chemotherapy, patients will receive 5 x 3-week cycles of chemotherapy in combination with either pembrolizumab or a placebo on day one of each 3-week cycle for up to 35 cycles, and olaparib or a placebo administered orally twice per day starting on cycle 7. All participants may also receive Bevacizumab on Day 1 of each 3-week cycle.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More